Addex Therapeutics Ltd - ADR
ADXN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.97M
Close$
$2.03
32.6% downside
Current Fair Value
32.6% downsideOvervalued by 32.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.97 Million |
|---|---|
| Enterprise Value | $3.28 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.88 |
| Beta | 1.96 |
| Outstanding Shares | 1,454,000 |
Return
| Return on Equity | -358.96% |
|---|---|
| Return on Assets | -196.79% |
| Return on Invested Capital | -216.30% |
Valuation & Multiples
| P/E Ratio | -0.49 |
|---|---|
| PEG | 8.84 |
| Price to Sales | - |
| Price to Book Ratio | 3.02 |
| Enterprise Value to Revenue | 17.24 |
| Enterprise Value to EBIT | -0.72 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Addex Therapeutics Ltd
27 employees
CEO: Tim Dyer Addex Therapeutics Ltd is a biopharmaceutical firm based in Switzerland, dedicated to identifying, developing, and commercializing small-molecule pharmaceutical products designed to address central nervous system (CNS) disorders. The com...